用于预防动脉粥样硬化血栓形成事件的抗血小板联合治疗。
Antiplatelet combinations for prevention of atherothrombotic events.
作者信息
Bollati Mario, Gaita Fiorenzo, Anselmino Matteo
机构信息
Department of Internal Medicine, Division of Cardiology, University of Torino, Italy.
出版信息
Vasc Health Risk Manag. 2011 Jan 12;7:23-30. doi: 10.2147/VHRM.S12271.
Abstract
Antiplatelet therapy plays a fundamental role in reducing atherothrombotic events by several pathways. The present work reviews available evidence on antiplatelet therapy both for primary prevention and in the presence of established peripheral, cerebral, or cardiac ischemic disease. Due to the importance of adherence to therapy to achieve optimal effects, special attention is given to the use of fixed-dose oral formulations in the clinical subset of patients in whom double antiplatelet therapy has proven indications.
摘要
抗血小板治疗通过多种途径在减少动脉粥样硬化血栓形成事件中发挥着重要作用。本研究综述了抗血小板治疗在一级预防以及已确诊的外周、脑或心脏缺血性疾病中的现有证据。由于坚持治疗对于实现最佳疗效至关重要，因此特别关注在已证实有双重抗血小板治疗指征的临床亚组患者中使用固定剂量口服制剂的情况。
相似文献
1
Antiplatelet combinations for prevention of atherothrombotic events.
Vasc Health Risk Manag. 2011 Jan 12;7:23-30. doi: 10.2147/VHRM.S12271.
2
New approaches to inhibiting platelets and coagulation.
Annu Rev Pharmacol Toxicol. 2015;55:373-97. doi: 10.1146/annurev-pharmtox-010814-124438.
3
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Nat Rev Cardiol. 2009 Jun;6(6):391-2. doi: 10.1038/nrcardio.2009.76.
4
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S1-6. doi: 10.1002/ccd.21995.
5
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Am Heart J. 2004 Aug;148(2):263-8. doi: 10.1016/j.ahj.2004.03.028.
6
Platelet antiaggregants in primary and secondary prevention of atherothrombotic events.
Arq Bras Cardiol. 2013 Jun;100(6):e78-84. doi: 10.5935/abc.20130122.
7
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.
Vasc Health Risk Manag. 2012;8:77-89. doi: 10.2147/VHRM.S26030. Epub 2012 Feb 15.
8
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Thromb Haemost. 2008 Mar;99(3):637-9. doi: 10.1160/TH07-07-0465.
9
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Clin Ther. 2008 Feb;30(2):249-59. doi: 10.1016/j.clinthera.2008.02.006.
10
Platelet function testing and implications for clinical practice.
J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):157-69. doi: 10.1177/1074248409339309.
引用本文的文献
1
Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy.
Chin J Integr Med. 2022 Sep;28(9):855-863. doi: 10.1007/s11655-020-3271-8. Epub 2020 Jul 20.
2
Factors Associated with Inadequate Management of Antiplatelet Agents in Perioperative Period of Non-Cardiac Surgeries.
Arq Bras Cardiol. 2018 Oct;111(4):596-604. doi: 10.5935/abc.20180162. Epub 2018 Sep 21.
3
Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?
J Drug Assess. 2013 May 7;2(1):67-71. doi: 10.3109/21556660.2013.801605. eCollection 2013.
4
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
Trials. 2012 Aug 25;13:148. doi: 10.1186/1745-6215-13-148.
5
Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization.
World J Gastroenterol. 2012 Jul 14;18(26):3443-50. doi: 10.3748/wjg.v18.i26.3443.
本文引用的文献
1
Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
World J Cardiol. 2010 Jun 26;2(6):131-4. doi: 10.4330/wjc.v2.i6.131.
2
Aspirin for primary prevention of cardiovascular events in people with diabetes.
J Am Coll Cardiol. 2010 Jun 22;55(25):2878-86. doi: 10.1016/j.jacc.2010.04.003.
3
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Circulation. 2010 Jun 15;121(23):2575-83. doi: 10.1161/CIRCULATIONAHA.109.895342. Epub 2010 Jun 1.
4
The significance of endothelial heterogeneity in thrombosis and hemostasis.
Semin Thromb Hemost. 2010 Apr;36(3):286-300. doi: 10.1055/s-0030-1253451. Epub 2010 May 20.
5
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
Expert Opin Pharmacother. 2010 Jun;11(9):1459-66. doi: 10.1517/14656561003792538.
6
Don't use aspirin for primary prevention of cardiovascular disease.
BMJ. 2010 Apr 21;340:c1805. doi: 10.1136/bmj.c1805.
7
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
JAMA. 2010 Mar 3;303(9):841-8. doi: 10.1001/jama.2010.221.
8
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13.
9
Real-life management of dual antiplatelet therapy interruption: the REGINA survey.
Arch Cardiovasc Dis. 2009 Oct;102(10):697-710. doi: 10.1016/j.acvd.2009.08.009. Epub 2009 Oct 27.
10
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.
BMJ. 2009 Nov 6;339:b4531. doi: 10.1136/bmj.b4531.
Zotero 插件